The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
 
Masamichi Takahashi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - Daiichi Sankyo
Research Funding - Eisai (Inst)
 
Satoshi Kawashima
No Relationships to Disclose
 
Yohei Otake
Employment - Eisai
 
Natsuko Satomi-Tsushita
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Aya Kuchiba
Honoraria - Chugai Pharma
 
Ryo Sadachi
No Relationships to Disclose
 
Keiko Ohata
Employment - Daiichi Sankyo RD Novare (I)
Stock and Other Ownership Interests - Daiichi Sankyo
 
Hitoshi Ozawa
No Relationships to Disclose
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Motoo Nagane
Honoraria - Chugai Pharma; Eisai; Kyowa Kirin International; Nippon Kayaku; Novocure; Ono Pharmaceutical; Sumitomo Dainippon Pharma Oncology
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Abbvie; Bayer (Inst); Chugai Pharma; Daiichi Sankyo; Eisai (Inst); HOYA Techonosurgical (Inst); Kyowa Kirin International; Nippon Kayaku (Inst); Ono Pharmaceutical; Otsuka (Inst); Saney Seiko (Inst); Shionogi (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst)
Travel, Accommodations, Expenses - Ono Pharmaceutical; Sumitomo Dainippon Pharma Oncology
 
Yoshiki Arakawa
Speakers' Bureau - Brainlab; Chugai Pharma; Daiichi Sankyo; Eisai; Merck; Nihon Medi-Physics; Nippon Kayaku; Novocure; Ono Pharmaceutical; UCB; Zeiss
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Nihon Medi-Physics (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Philips Healthcare (Inst); Siemens (Inst); Stryker (Inst); Sumitomo Dainippon Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Akitake Mukasa
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai Europe; Nippon Kayaku; Novartis; Novocure; Ono Pharmaceutical; Otsuka; Pfizer
Research Funding - Bayer (Inst); Chugai Pharma; Daiichi Sankyo/Arqule; Eisai; Otsuka; Teijin Pharma
 
Shota Tanaka
Honoraria - Chugai Pharma; Daiichi-Sankyo Co., Ltd.; Eisai; Novocure
Research Funding - Eisai; Ono Pharmaceutical; Sumitomo Dainippon Pharma co., Ltd.; Takeda Science Foundation
Patents, Royalties, Other Intellectual Property - P2019-095102; PCT/JP2020/019814
 
Ryo Nishikawa
Honoraria - Eisai; Nihonkayaku
Consulting or Advisory Role - Novocure; Springer
Speakers' Bureau - Ono Pharmaceutical; Varian Medical Systems
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yoshihiro Muragaki
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Hitachi Chemical; MSD; Novartis; Otsuka
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Hitachi Chemical (Inst); MSD (Inst); Otsuka (Inst)
 
Kenkichi Masutomi
Research Funding - Carna Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - Solstar Pharma (Inst)
 
Koichi Ichimura
Honoraria - Chugai Pharma
Research Funding - Daiichi Sankyo; Riken Genesis
 
Kenichi Nakamura
Honoraria - Chugai Pharma; IQvia; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Novocure; Ono Pharmaceutical
Consulting or Advisory Role - Dainippon Sumitomo Pharma
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Stella pharma (Inst); Taiho Pharmaceutical (Inst)